Skip to the page

Data / Drug companies / Creekwood Pharmaceuticals LLC

Creekwood Pharmaceuticals LLC: 38 products in the FDA NDC directory, labeler code 82619

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Creekwood Pharmaceuticals LLC (labeler code 82619) lists 38 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 38 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 29, 2026.

The request: Watch Creekwood Pharmaceuticals LLC (FDA labeler code 82619): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
82619
Products in commercial distribution
38
Packages
83
Finished drugs by generic name
10
Prescription products
38
Over the counter products
0
Controlled substance products
Schedule V 8
Flagged as original packager
38 of 38 products that carry the flag
Started marketing in the last 12 months
18
Earliest marketing start
December 31, 2012
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)38100%

Products by type

TypeProductsShare
Prescription drugs38100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Capsule2155.3%
Tablet1334.2%
Capsule, extended release410.5%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Propranolol Hydrochloride82619-135Capsule, extended releaseGeneric drugs (ANDA)August 29, 2026
Propranolol Hydrochloride82619-134Capsule, extended releaseGeneric drugs (ANDA)August 29, 2026
Propranolol Hydrochloride82619-133Capsule, extended releaseGeneric drugs (ANDA)August 29, 2026
Propranolol Hydrochloride82619-132Capsule, extended releaseGeneric drugs (ANDA)August 29, 2026
Atomoxetine82619-121CapsuleGeneric drugs (ANDA)July 6, 2026
Atomoxetine82619-120CapsuleGeneric drugs (ANDA)July 6, 2026
Atomoxetine82619-119CapsuleGeneric drugs (ANDA)July 6, 2026
Atomoxetine82619-118CapsuleGeneric drugs (ANDA)July 6, 2026
Atomoxetine82619-117CapsuleGeneric drugs (ANDA)July 6, 2026
Atomoxetine82619-116CapsuleGeneric drugs (ANDA)July 6, 2026
Atomoxetine82619-115CapsuleGeneric drugs (ANDA)July 6, 2026
Nitrofurantoin (monohydrate/macrocrystals)82619-147CapsuleGeneric drugs (ANDA)April 20, 2026
Haloperidol82619-110TabletGeneric drugs (ANDA)January 5, 2026
Haloperidol82619-109TabletGeneric drugs (ANDA)January 5, 2026
Haloperidol82619-108TabletGeneric drugs (ANDA)January 5, 2026
Haloperidol82619-107TabletGeneric drugs (ANDA)January 5, 2026
Haloperidol82619-106TabletGeneric drugs (ANDA)January 5, 2026
Haloperidol82619-105TabletGeneric drugs (ANDA)January 5, 2026
Hydroxychloroquine sulfate82619-131TabletGeneric drugs (ANDA)May 8, 2025
Silodosin82619-114CapsuleGeneric drugs (ANDA)November 14, 2024
Silodosin82619-113CapsuleGeneric drugs (ANDA)November 14, 2024
Pregabalin82619-129CapsuleGeneric drugs (ANDA)September 20, 2024
Pregabalin82619-128CapsuleGeneric drugs (ANDA)September 20, 2024
Pregabalin82619-127CapsuleGeneric drugs (ANDA)September 20, 2024
Pregabalin82619-126CapsuleGeneric drugs (ANDA)September 20, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.